Status:
COMPLETED
Study of Molecular Pathways in Medullary Thyroid Carcinoma and Correlation of Molecular Data With Clinical Behavior of the MTC in Individuals Patients
Lead Sponsor:
National Cancer Institute (NCI)
Conditions:
Medullary Thyroid Carcinoma
Multiple Endocrine Neoplasia Type 2
Eligibility:
All Genders
2-80 years
Brief Summary
Background: Medullary thyroid carcinoma (MTC) is a rare malignancy, occurring either as a sporadic disease (75% of cases), or in a hereditary pattern as multiple endocrine neoplasia (MEN) type 2 (MEN...
Detailed Description
Background: Medullary thyroid carcinoma (MTC) is a rare malignancy, occurring either as a sporadic disease (75% of cases), or in a hereditary pattern as multiple endocrine neoplasia (MEN) type 2 (MEN...
Eligibility Criteria
Inclusion
- INCLUSION CRITERIA:
- Patients must have confirmed diagnosis of C-cell hyperplasia, primary MTC, or metastatic MTC with archived pathology specimens available at Washington University.
Exclusion
Key Trial Info
Start Date :
July 5 2010
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
February 12 2014
Estimated Enrollment :
150 Patients enrolled
Trial Details
Trial ID
NCT01424878
Start Date
July 5 2010
End Date
February 12 2014
Last Update
April 5 2018
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
National Cancer Institute (NCI), 9000 Rockville Pike
Bethesda, Maryland, United States, 20892